Učestalost metaboličkog sindroma kod bolesnika sa supkliničkom hipotireozom
Sažetak
Apstrakt
Uvod/Cilj. Povećan kardiovaskularni rizik u disfunkciji štitaste žlezde u vezi je sa poremećajima metabolizma lipida i lipoproteina, endotelijalnom disfunkcijom, metaboličkim, hormonskim, hemodinamskim promenama i poremećajima koagulacije. Supklinička hipotireoza karakteriše se supranormalnim nivoom tireostimulišućeg hormona (TSH) uz normalne vrednosti tireoidnih hormona. Udruženost supkliničke hipotireoze sa povišenim rizikom od nastanka kardiovaskularnih bolesti još uvek nije u potpunosti razjašnjena. Cilj rada bio je određivanje učestalosti metaboličkog sindroma i pridruženih faktora rizika od nastanka kardiovaskularnih bolesti kod bolesnika sa supkliničkom hipotireozom. Metode. Istraživanjem je obuhvaćeno 140 ispitanika starosti 18–65 godina – 105 ispitanika sa supkliničkom hipotireozom i kontrolna grupa od 35 ispitanika bez nje. Kod svih ispitanika sproveden je program istraživanja koji je uključivao: detaljnu anamnezu i fizikalni pregled, merenje obima struka, laboratorijska ispitivanja [glikemija našte, lipidni i lipoproteinski status, slobodni trijodtrionin (fT3), slobodni tiroksin (fT4) i TSH]. Rezultati. Od 105 bolesnika sa subkliničkom hipotireozom, prosečne starosti 44,15 ± 11,23 godina, 77 (73.3%) bolesnika imala su metabolički sindrom. U kontrolnoj grupi od 35 ispitanika, prosečne starosti 33,80 ± 10,60 godina, samo 3 (8.6%) ispitanika imala su metabolički sindrom. Srednje vrednosti obima struka, našte glukoze u krvi, triglicerida, sistolnog i dijastolnog krvnog pritiska bile su više u grupi sa supkliničkom hipotireozom u odnosu na kontrolnu grupu (p < 0.0001). Srednja vrednost HDL-holesterola bila je niža u grupi sa supkliničkom hipotireozom u poređenju sa kontrolnom grupom (p < 0.002). Zaključak. Učestalost metaboličkog sindroma je oko 9 puta veća kod ispitanika sa supkliničkom hipotireozom u odnosu na eutireoidne ispitanike.
Reference
References:
Cooper DS, Biondi B. Subclinical thyroid disease. Lancet 2012; 379(9821): 1142–54.
Vanderpump MP, Tunbrldge WM, French JM, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in the community: A twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995; 43(1): 55–68.
Kim YA, Park YJ. Prevalence and risk factors of subclinical thyroid disease. Endocrinol Metab (Seoul) 2014; 29(1): 20–9.
Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T(4), and thyroid antibo-dies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87(2): 489–99.
Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witte-man JC. Subclinical hypothyroidism is an independent risk fac-tor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam Study. Ann Intern Med 2000; 132(4): 270–8.
Chubb SA, Davis WA, Inman Z, Davis TM. Prevalence and progression of subclinical hypothyroidism in women with type 2 diabetes: The Fremantle Diabetes Study. Clin Endocrinol (Oxf) 2005; 62(4): 480–6.
Kim TH, Choi HS, Bae JC, Moon JH, Kim HK, Choi SH, et al. Subclinical hypothyroidism in addition to common risk scores for prediction of cardiovascular disease: A 10-year community-based cohort study. Eur J Endocrinol 2014; 171(5): 649–57.
Ye Y, Xie H, Zeng Y, Zhao X, Tian Z, Zhang S. Association be-tween subclinical hypothyroidism and blood pressure: A meta-analysis of observational studies. Endocr Pract 2014; 20(2): 150–8.
Neves C, Alves M, Medina JL, Delgado JL. Thyroid diseases, dyslipidemia and cardiovascular pathology. Rev Port Cardiol 2008; 27(10): 1211–36.
Pearce EN. Update in lipid alterations in subclinical hypothy-roidism. J Clin Endocrinol Metab 2012; 97(2): 326–33.
Liu XL, He S, Zhang SF, Wang J, Sun XF, Gong CM, et al. Alteration of lipid profile in subclinical hypothyroidism: A meta-analysis. Med Sci Monit 2014; 20: 1432–441.
Park YJ, Lee YJ, Choi SI, Chun EJ, Jang HC, Chang HJ. Impact of subclinical hypothyroidism on the coronary artery disease in apparently healthy subjects. Eur J Endocrinol 2011; 165(1): 115–21.
Marfella R, Ferraraccio F, Rizzo MR, Portoghese M, Barbieri M, Basilio C, et al. Innate immune activity in plaque of patients with untreated and L-thyroxine-treated subclinical hypothy-roidism. J Clin Endocrinol Metab 2011; 96(4): 1015–20.
Razvi S, Ingoe L, Keeka G, Oates C, Mcmillan C, Weaver JU. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothy-roidism: Randomized, crossover trial. J Clin Endocrinol Metab 2007; 92(5): 1715–23.
Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev 2008; 29(1): 76–131.
Taylor PN, Razvi S, Pearce SH, Dayan CM. Clinical review: A review of the clinical consequences of variation in thyroid function within the reference range. J Clin Endocrinol Metab 2013; 98(9): 3562–71.
Mulić M, Tomić-Naglić D, Benc D. Lipid and lipoproteins changes during substitutional therapy of subclinical hypothy-roidism. Medicina danas 2009; 8(1 ̶ 3): 7–14. (Serbian)
Madathil A, Hollingsworth KG, Blamire AM, Razvi S, Newton JL, Taylor R, et al. Levothyroxine improves abnormal cardiac bio-energetics in subclinical hypothyroidism: a cardiac magnetic resonance spectroscopic study. J Clin Endocrinol Metab 2015; 100(4): E607–10.
Javed Z, Sathyapalan T. Levothyroxine treatment of mild sub-clinical hypothyroidism: A review of potential risks and bene-fits. Ther Adv Endocrinol Metab 2016; 7(1): 12–23.
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120(16): 1640–5.
Framingham Heart Study. Framingham Study Risk Score Pro-files. 2012. [cited 2012 Dec 5]. Available from: www.framinghamheartstudy.org/risk/index.html
Suh S, Lee MK. Metabolic syndrome and cardiovascular diseas-es in Korea. J Atheroscler Thromb 2014; 21(1): S31 ̶ 5.
Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes 2010; 2: 180–93.
Azimi-Nezhad M, Herbeth B, Siest G, Dadé S, Ndiaye NC, Esmaily H, et al. High prevalence of metabolic syndrome in Iran in comparison with France: what are the components that explain this? Metab Syndr Relat Disord 2012; 10(3): 181–8.
Yki-Jarvinen H. The insulin resistance syndrome. In: de Fronzo RA, Ferrannini E, Keen H, Zimmet P, editors. International textbook of diabetes mellitus. 3rd ed. Chicester: John Wiley & Sons; 2004. p. 359–73.
Kahn R, Buse J, Ferrannini E, Stern M; American Diabetes Asso-ciation.; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint state-ment from the American Diabetes Association and the Euro-pean Association for the Study of Diabetes. Diabetes Care 2005; 28(9): 2289–304.
Pearce SH, Brabant G, Duntas LH, Monzani F, Peeters RP, Razvi S, et al. Management of Subclinical Hypothyroidism. Eur Thy-roid J 2013; 2(4): 215–28.
Baumgartner C, Blum MR, Rodondi N. Subclinical hypothyroid-ism: Summary of evidence in 2014. Swiss Med Wkly 2014; 144: w14058.
Asvold BO, Bjøro T, Platou C, Vatten LJ. Thyroid function and the risk of coronary heart disease: 12-year follow-up of the HUNT study in Norway. Clin Endocrinol (Oxf) 2012; 77(6): 911–7.
Nanchen D, Gussekloo J, Westendorp RG, Stott DJ, Jukema JW, Trompet S, et al. Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk. J Clin Endocrinol Metab 2012; 97(3): 852–61.
Gencer B, Collet TH, Virgini V, Bauer DC, Gussekloo J, Cappola AR, et al. Subclinical thyroid dysfunction and the risk of heart failure events: An individual participant data analysis from 6 prospective cohorts. Circulation 2012; 126(9): 1040–9.
Pereg D, Tirosh A, Elis A, Neuman Y, Mosseri M, Segev D, et al. Mortality and coronary heart disease in euthyroid patients. Am J Med. 2012; 125(8): 826.e7–12.
Kovar FM, Fang IF, Perkmann T, Haslacher H, Slavka G, Födinger M, et al. Subclinical hypothyroidism and mortality in a large Austrian cohort: a possible impact on treatment? Wien Klin Wochenschr 2015; 127(23–24): 924–30.
Tseng FY, Lin WY, Lin CC, Lee LT, Li TC, Sung PK, et al. Subclinical hypothyroidism is associated with increased risk for all-cause and cardiovascular mortality in adults. J Am Coll Cardiol 2012; 60(8): 730–7.
Westerink J, van der Graaf Y, Faber DR, Spiering W, Visseren FL. SMART study group. Relation between thyroid-stimulating hormone and the occurrence of cardiovascular events and mortality in patients with manifest vascular diseases. Eur J Prev Cardiol 2012; 19(4): 864–73.
Ceresini G, Ceda GP, Lauretani F, Maggio M, Usberti E, Marina M, et al. Thyroid status and 6-year mortality in elderly people living in a mildly iodine-deficient area: The aging in the Chianti Area Study. J Am Geriatr Soc 2013; 61(6): 868–74.
Hyland KA, Arnold AM, Lee JS, Cappola AR. Persistent subclinical hypothyroidism and cardiovascular risk in the elderly: The cardiovascular health study. J Clin Endocrinol Metab 2013; 98(2): 533–40.
Selmer C, Olesen JB, Hansen ML, von Kappelgaard LM, Madsen JC, Hansen PR, et al. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: A large population study. J Clin Endocrinol Metab 2014; 99(7): 2372–82.
Åsvold BO, Vatten LJ, Bjøro T, Bauer DC, Bremner A, Cappola AR, et al. Thyroid function within the normal range and risk of coronary heart disease: An individual participant data analysis of 14 cohorts. JAMA Intern Med 2015; 175(6): 1037–47.
Chaker L, Baumgartner C, den Elzen WP, Ikram MA, Blum MR, Collet TH, et al. Subclinical Hypothyroidism and the Risk of Stroke Events and Fatal Stroke: An Individual Participant Data Analysis. J Clin Endocrinol Metab 2015; 100(6): 2181–91.
Yang L, Lv X, Yue F, Wei D, Liu W, Zhang T. Subclinical hypothyroidism and the risk of metabolic syndrome: A meta-analysis of observational studies. Endocr Res 2016; 41(2): 158–65.
Lai CC, Tang SH, Pei D, Wang CY, Chen YL, Wu CZ, et al. The prevalence of subclinical thyroid dysfunction and its association with metabolic syndrome in Taiwanese elderly. Int J Gerontol 2011; 5(1): 25–9.
Pangaluri R, Akila S, William E. Prevalence of metabolic syn-drome and its components in women with subclinical hypo-thyroidism. Asian J Pharm Clin Res 2013; 6(4): 82–4.
Choudhary PR, Jani RC. Study of thyroid function in patients with metabolic syndrome. Int J Res Med Sci 2016; 4(6): 2024–9.
Udenze I, Nnaji I, Oshodi T. Thyroid function in adult Nigerians with metabolic syndrome. Pan Afr Med J 2014; 18: 352.
Gyawali P, Takanche JS, Shrestha RK, Bhattarai P, Khanal K, Risal P, et al. Pattern of thyroid dysfunction in patients with meta-bolic syndrome and its relationship with components of meta-bolic syndrome. Diabetes Metab J 2015; 39(1): 66–73.
Agarwal G, Sudhakar MK, Singh M, Senthil N, Rajendran A. The prevalence of thyroid dysfunction among south Indian women with metabolic syndrome. J Clin Diagn Res 2011; 5(2): 213–6.
Tarcin O, Abanonu GB, Yazici D, Tarcin O. Association of meta-bolic syndrome parameters with TT3 and FT3/FT4 ratio in obese Turkish population. Metab Syndr Relat Disord 2012; 10(2): 137–42.
Nakajima Y, Yamada M, Akuzawa M, Ishii S, Masamura Y, Satoh T, et al. Subclinical hypothyroidism and indices for metabolic syndrome in Japanese women: One-year follow-up study. J Clin Endocrinol Metab 2013; 98(8): 3280–7.
Iwen KA, Schröder E, Brabant G. Thyroid hormones and the me-tabolic syndrome. Eur Thyroid J 2013; 2(2): 83–92.
Oh JY, Sung YA, Lee HJ. Elevated thyroid stimulating hormone levels are associated with metabolic syndrome in euthyroid young women. Korean J Intern Med 2013; 28(2): 180–6.